Susceptibility profile | SXT | CTX | FEP | AN | IPM | MEM | CRO | GM | CAZ | CIP | |
---|---|---|---|---|---|---|---|---|---|---|---|
MDR | S | 25 (37.3%) | 26 (38.8%) | 27 (40.3%) | 55 (82.1%) | 41 (61.2%) | 38 (56.7%) | 29 (43.3%) | 48 (71.6%) | 28 (41.7%) | 19 (28.3%) |
I | 4 (5.9%) | 8 (11.9%) | 5 (7.5%) | 5 (7.5%) | 2 (2.9%) | 1 (1.5%) | 9 (13.4%) | 2 (2.9%) | 8 (11.9%) | 4 (5.9%) | |
R | 38 (56.7%) | 33 (49.3%) | 35 (52.2%) | 7 (10.4%) | 24 (35.8%) | 28 (41.7%) | 29 (43.3%) | 17 (25.4%) | 31 (46.3%) | 44 (65.6%) | |
Non-MDR | S | 18 (54.5%) | 22 (66.6%) | 22 (66.6%) | 31 (93.9%) | 22 (66.6%) | 23 (69.6%) | 16 (48.5%) | 25 (75.5%) | 18 (54.5%) | 19 (57.5%) |
I | 1 (3%) | 4 (12.1%) | 3 (9.1%) | 2 (6.1%) | 0 (0.0%) | 1 (3%) | 3 (9.1%) | 0 (0.0%) | 2 (6.1%) | 5 (15.2%) | |
R | 14 (42.4%) | 18 (54.5%) | 8 (24.2%) | 0 (0.0%) | 11 (33.3%) | 9 (27.3%) | 14 (42.4%) | 8 (24.2%) | 13 (39.4%) | 9 (27.3%) |